JP2016531910A5 - - Google Patents

Download PDF

Info

Publication number
JP2016531910A5
JP2016531910A5 JP2016534873A JP2016534873A JP2016531910A5 JP 2016531910 A5 JP2016531910 A5 JP 2016531910A5 JP 2016534873 A JP2016534873 A JP 2016534873A JP 2016534873 A JP2016534873 A JP 2016534873A JP 2016531910 A5 JP2016531910 A5 JP 2016531910A5
Authority
JP
Japan
Prior art keywords
organ
composition
complement inhibitor
complement
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016534873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531910A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/051323 external-priority patent/WO2015023972A1/en
Publication of JP2016531910A publication Critical patent/JP2016531910A/ja
Publication of JP2016531910A5 publication Critical patent/JP2016531910A5/ja
Pending legal-status Critical Current

Links

Images

JP2016534873A 2013-08-16 2014-08-15 移植前の臓器への補体阻害剤の投与による移植拒絶の処置 Pending JP2016531910A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361867009P 2013-08-16 2013-08-16
US61/867,009 2013-08-16
PCT/US2014/051323 WO2015023972A1 (en) 2013-08-16 2014-08-15 Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant

Publications (2)

Publication Number Publication Date
JP2016531910A JP2016531910A (ja) 2016-10-13
JP2016531910A5 true JP2016531910A5 (https=) 2017-09-28

Family

ID=51494495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016534873A Pending JP2016531910A (ja) 2013-08-16 2014-08-15 移植前の臓器への補体阻害剤の投与による移植拒絶の処置

Country Status (5)

Country Link
US (1) US20160184391A1 (https=)
EP (1) EP3033093A1 (https=)
JP (1) JP2016531910A (https=)
CA (1) CA2920293A1 (https=)
WO (1) WO2015023972A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP3524258B1 (en) 2011-06-22 2025-10-01 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
JP7221691B2 (ja) * 2015-10-30 2023-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド Ｔ細胞媒介性同種移植片血管障害の増悪を抑制する方法
HUE065073T2 (hu) 2015-12-18 2024-04-28 Chugai Pharmaceutical Co Ltd Anti-C5 antitestek és alkalmazási eljárások
EP3463459A1 (en) * 2016-06-07 2019-04-10 Novartis AG Tesidolumab for use in the treatment of transplant rejection
US20190127453A1 (en) * 2016-06-07 2019-05-02 Novartis Ag An anti-c5 antibody dosing regimen
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
WO2018075462A1 (en) * 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating and preventing transplant-associated injury
GB201709222D0 (en) * 2017-06-09 2017-07-26 Univ Manchester C3b Inactivating Polypeptide
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
JP7684216B2 (ja) * 2018-08-17 2025-05-27 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア ドナー臓器における糖鎖抗原除去のための酵素組成物、それに関連する方法および使用
US20220009979A1 (en) * 2018-08-22 2022-01-13 Alexion Pharmaceuticals, Inc. Fusion proteins and methods of treating complement dysregulation using the same
CN114127560A (zh) * 2019-03-21 2022-03-01 Uab研究基金会 增加细胞对补体介导裂解的敏感性的方法
AU2020272875A1 (en) 2019-04-10 2021-10-14 University Of Massachusetts Factor h vectors and uses thereof
CN110423271A (zh) * 2019-08-07 2019-11-08 北京市农林科学院 鸡cr2基因的克隆、蛋白的表达和纯化及其多克隆抗体的制备
CA3182800A1 (en) 2020-06-14 2021-12-23 Vertex Pharmaceuticals Inc. Complement factor i-related compositions and methods
AU2022283254A1 (en) * 2021-05-25 2023-11-30 Alexion Pharmaceuticals, Inc. Kidney active fusion proteins and methods of treatment using the same
WO2022251168A1 (en) * 2021-05-25 2022-12-01 Alexion Pharmaceuticals, Inc. Kidney active fusion proteins and methods of treatment using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5723282A (en) 1991-07-08 1998-03-03 The American National Red Cross Method of preparing organs for vitrification
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
AU2595195A (en) 1994-05-20 1995-12-18 Vec Tec, Inc. Method and apparatus monitoring viability of transplantable organs
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
AU748443B2 (en) 1998-02-04 2002-06-06 General Hospital Corporation, The Costimulatory blockade and mixed chimerism in transplantation
WO2000027421A2 (en) 1998-11-06 2000-05-18 The Schepens Eye Research Institute, Inc. LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
AU2003209308A1 (en) 2002-01-22 2003-09-02 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection
JP2007527299A (ja) * 2004-03-05 2007-09-27 グローバル アプライアンス テクノロジーズ インコーポレイテッド コンベヤオーブン
EP2338511A3 (en) 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
JP5722524B2 (ja) * 2006-03-02 2015-05-20 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体活性を抑制することによる同種移植片の生存の延長
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
CA2742802C (en) * 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20130323708A1 (en) 2009-07-01 2013-12-05 Massachusetts Institute Of Technology Isolated adult cells, artificial organs, rehabilitated organs, research tools, organ encasements, organ perfusion systems, and methods for preparing and utilizing the same

Similar Documents

Publication Publication Date Title
JP2016531910A5 (https=)
JP6466971B2 (ja) 臓器、組織又は細胞移植用組成物、キット及び移植方法
Patel et al. Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage
JP2016531910A (ja) 移植前の臓器への補体阻害剤の投与による移植拒絶の処置
JP2022088551A (ja) 増殖造血幹細胞／前駆細胞集団の利用
JP7465567B2 (ja) Ｐｅｇ－リン脂質分子を用いたエクスビボ臓器処置
JP2009514553A5 (https=)
CA2815237C (en) Method of improving transplant function using soluble complement receptor type i (scr1)
Dangoor et al. Transplantation: a brief history
Ha et al. Clinical outcomes of cryopreserved arterial allograft used as a vascular conduit for hemodialysis
US20200329698A1 (en) Compositions for organ graft preservation and methods of use
US10086070B2 (en) Combined therapy of alpha-1-antitrypsin and temporal T-cell depletion for preventing graft rejection
Anderson et al. Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation
AU773516B2 (en) Organ transplant solutions containing conjugates of soluble peptidic compounds with membrane-binding
JP3543106B2 (ja) 膜結合型ｃ１インアクチベーター
JP2018519359A5 (https=)
Hosgood et al. Cold ischaemic injury in kidney transplantation
RU2808054C2 (ru) Обработка органов ex vivo молекулами пэг-фосфолипида
JP2018517724A (ja) 被移植体における移植不全を防ぐ方法
JP6515429B2 (ja) 人工血管、および、人工血管の製造方法
Xing et al. Liver regeneration: Influence-factors and mechanism of mesenchymal stem cell transplantation.
Lledó-Garcia et al. Optimizing outcomes by preconditioning the donor
Wang Strategies for Prevention of Antibody Mediated Allograft Rejection
Șereș et al. A review of current strategies to overcome rejection in xenotransplant.